Physician profile
Benjamin Ware
NPI 1073048575
$6,575.64
in general payments reported to CMS, 2019-2025
38 companies · $3,581 in 2025
The $3,581 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.50 · 2021: $45.26 · 2024: $2,926 · 2025: $3,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,506.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $614.53 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $593.85 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $581.78 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $496.45 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $395.63 | 2024-2025 | |
| Harmony Biosciences LLC | $372.27 | 2024-2025 | |
| Exact Sciences Corporation | $292.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $285.19 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.70 | 2024-2025 | Xifaxan |
| Amgen INC. | $237.09 | 2024-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $229.48 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.08 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $156.67 | 2021-2025 | |
| Astellas Pharma US INC | $147.61 | 2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $146.68 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $144.73 | 2025 | Auvelity |
| Braeburn INC. | $140.91 | 2024-2025 | Brixadi |
| Phathom Pharmaceuticals, INC. | $131.55 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $112.03 | 2024-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $95.59 | 2025 | |
| Esperion Therapeutics, INC. | $91.26 | 2024-2025 | Nexletol |
| Indivior INC. | $89.18 | 2024-2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $80.65 | 2025 | Xtampza, Belbuca |
| Sumitomo Pharma America, INC. | $75.58 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $65.19 | 2024-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $64.57 | 2024 | Quviviq |
| Seqirus USA INC | $62.67 | 2024-2025 | Flucelvax, Fluad |
| Dexcom, INC. | $56.22 | 2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $55.67 | 2024 | Vivitrol |
| Shield Therapeutics INC | $43.72 | 2024 | |
| Eisai INC. | $43.57 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $42.56 | 2024 | Nuzyra |
| Ardelyx, INC. | $39.25 | 2024 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.92 | 2025 | Caplyta |
| Lundbeck LLC | $25.33 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $20.62 | 2024 | Inspire |
| Almatica Pharma LLC | $20.30 | 2025 | Loreev Xr |
| Novartis Pharmaceuticals Corporation | $15.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.